We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other best growth stocks to buy according to billionaires.

Can the Stock Market Have a Big Rebound?

The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down or a recession. The volatility can be estimated by the 19% decrease in the S&P 500 from its recent all-time high. To talk about the current market volatility and the way forward, Fundstrat’s Tom Lee joined CNBC for an interview. He noted that the market is currently pessimistic as recent data shows that they have priced in a 60% probability of a recession, however, it is essential to note that if the tariff situation de-escalates then the probability of a recession isn’t that high. As a result, Lee thinks that there is a big window of opportunity for stocks to rebound, however, this rebound is contingent on the path of tariff de-escalation.

While addressing the concerns that if the market is in a bear market, Lee noted that if we define a bear market by stocks grinding and losing money, then this has been happening since December 2024. However, if you define a bear market as unleashing a type of financial tightening that leads to a recession, the current market does not fit that criteria. Lee acknowledged that it does feel like a bear market for an average person.

Lee also talked about the viable investor strategy under the current circumstances. Firstly, he highlighted that people are fighting two brains at the moment, one is a tactical brain, where people want to know if this is the bottom and be convinced by seeing the stocks rally on bad news. On the other hand, there is the investor or the long-term brain, which suggests that people should have confidence in the US companies to navigate this volatility. Lee noted that he is a buyer of this volatility as he thinks that the de-escalation of tariffs will take place, which will result in a big rebound for stocks.

Our Methodology

To compile a list of the 10 best growth stocks to buy according to billionaires, we used the Finviz stock screener, Seeking Alpha, and Insider Monkey’s Billionaire database. Using the screener we aggregated a list of growth stocks that have grown their top-line by more than 30% over the past 3 years and sorted them by market cap. Next, we cross-checked each stock’s sales growth from Seeking Alpha and ranked the stocks in ascending order of the number of billionaire investors. Please note that we have also included the hedge funds sentiment around each stock, as of Q4 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

argenx SE (NASDAQ:ARGX)

3-Years Sales Growth: 62.05%

Number of Hedge Fund Holders: 47

Number of Billionaires: 9

Value of Billionaire Holdings: $810,790,522

argenx SE (NASDAQ:ARGX) is another best growth stock to buy according to billionaires. It operates as a biopharmaceutical company engaged in developing antibody therapy to treat and serve autoimmune diseases and certain cancers. The company sets itself apart from its competitors by the use of its proprietary Simple Antibody discovery platform, which leverages unique characteristics of the llama immune system to create differentiated therapeutic antibodies.

On April 11, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on the stock with a price target of $772. The analyst based his rating on recent developments for argenx SE (NASDAQ:ARGX) including the FDA’s approval of Vyvgart Hytrulo’s pre-filled syringe for at-home self-injection is a significant milestone. This is particularly unique as it allows patients a more convenient treatment without the need to go to a hospital. This is anticipated to increase the market reach for the drug. Moreover, management anticipates that the increase in price and the expected growth of gross to net will be balanced by the volume growth. argenx SE (NASDAQ:ARGX) also plans to launch an auto-injector which will further strengthen its position in the gMG and CIDP markets.

Artisan Small Cap Fund stated the following regarding Argenx SE (NASDAQ:ARGX) in its Q4 2024 investor letter:

“We ended our investment campaigns in Argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and strong sales execution of VYVGART®’s first approved indication in myasthenia gravis. While we continue to have high conviction, the company has outgrown our small-cap mandate, and we exited our position after a successful multiyear investment campaign.”

Overall, ARGX ranks 8th on our list of best growth stocks to buy according to billionaires. While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.